Get the Stockscreener App
5.36
2.90%
-0.16
Agenus Inc stock is traded at $5.36, with a volume of 265.44K.
It is down -2.90% in the last 24 hours and up +10.74% over the past month.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
See More
Previous Close:
$5.52
Open:
$5.5
24h Volume:
265.44K
Relative Volume:
0.22
Market Cap:
$146.95M
Revenue:
$160.43M
Net Income/Loss:
$-227.64M
P/E Ratio:
-0.0779
EPS:
-68.77
Net Cash Flow:
$-170.79M
1W Performance:
-10.07%
1M Performance:
+10.74%
6M Performance:
+41.05%
1Y Performance:
-10.22%
1-Day Range:
$5.34
$5.63
1-Week Range:
$5.34
$6.58
52-Week Range:
$1.38
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
5.36 | 151.34M | 160.43M | -227.64M | -170.79M | -68.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
What institutional investors are buying Agenus Inc. stockRetirement Planning Growth Plan With Proven Results - jammulinksnews.com
Is Agenus Inc. stock overvalued or undervaluedEarnings Report Alerts To Watch Now - jammulinksnews.com
Zacks.com featured highlights include QuantumScape, Civeo and Agenus - The Globe and Mail
QuantumScape, Civeo, and Agenus Lead the Way in Earnings Acceleration - AInvest
Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report - The Globe and Mail
What markets is RILYL expanding into Is Agenus Inc. stock a good long term investment option - jammulinksnews.com
How many analysts rate Agenus Inc. as a “Buy”Pre Market Ideas For Beginners - jammulinksnews.com
What are the latest earnings results for Agenus Inc.Free Stock Growth Plan For Smart Trading - jammulinksnews.com
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Why Agenus Inc. stock attracts strong analyst attentionDaily Smart Money Movement Monitor Activated - metal.it
Agenus Inc. Company’s Quarterly Earnings Growth: What the Numbers SayLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Agenus Inc. to Host Earnings Call - ACCESS Newswire
Traders Watching For Reversal Pattern in Agenus Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Agenus Inc. Bounces Off Moving Average SupportEarly Entry Picks Before News Breakout Reviewed - metal.it
What are analysts’ price targets for Agenus Inc. in the next 12 monthsChart Pattern Data Feed For Beginners - jammulinksnews.com
RSI Crosses Above 30 for Agenus Inc. — Reversal in SightFast Return Equity Trade Forecast Points to Small Caps - metal.it
What are the technical indicators suggesting about Agenus Inc.Build a diversified portfolio for stability - jammulinksnews.com
What is the dividend policy of Agenus Inc. stockCapitalize on market trends before they peak - jammulinksnews.com
How strong is Agenus Inc. company’s balance sheetAchieve rapid capital gains with smart investing - jammulinksnews.com
What are Agenus Inc. company’s key revenue driversExponentially increasing returns - jammulinksnews.com
What markets is Agenus Inc. expanding into Is GDXU stock a good long term investment optionExplosive earning power - jammulinksnews.com
Should I hold or sell Agenus Inc. stock in 2025Invest like a pro with expert recommendations - jammulinksnews.com
Is Agenus Inc. Stock a Good Fit for Conservative InvestorsValue Pick Scanner - metal.it
Published on: 2025-07-27 17:06:20 - jammulinksnews.com
How Agenus Inc. stock performs during market volatilityLow Risk Scalping Alerts - metal.it
Unlocking New Value in Immuno-Oncology: Agenus' Botensilimab/Balstilimab Combination Therapy in Refractory Cancers - AInvest
Agenus Inc. Stock Analysis and ForecastMarket-crushing profits - PrintWeekIndia
Agenus Inc. shares fall 1.64% after-hours following ESMO Congress 2025 abstracts acceptance. - AInvest
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 - Lelezard
What drives Agenus Inc. stock priceOutstanding risk-reward balance - PrintWeekIndia
Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 | AGEN Stock News - GuruFocus
Is Agenus Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia
Is Agenus Inc. stock a good hedge against inflationFree Predictions - jammulinksnews.com
What analysts say about Agenus Inc. stockFree Capital Efficiency Planning - Autocar Professional
AI Revolution in Healthcare: Avant Technologies, Agenus, Clover Health, Zimmer Biomet, Monogram Technologies Lead the Way. - AInvest
From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits - Finansavisen
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):